Home › Companies › NRXP

NRX Pharmaceuticals

NRXP Lead: NDA Submitted 9 Biotech Distilled articles ↓

Neurology Small Molecule

Most recent annual filing: 2026-03-23

Pipeline (5 active programs)

KETAFREE

ketamine · NRX-100

Small Molecule Target: NMDA receptor

Suicidal Ideation in Depression NDA Submitted intravenous

D-cycloserine

lurasidone · D-cycloserine/lurasidone · NRX-101

Small Molecule Target: NMDA receptor, NMDA

Bipolar Depression NDA Submitted oral

D-cycloserine

lurasidone · NRX-101

Small Molecule Target: NMDA receptor

Major Depressive Disorder Phase 3 oral

D-cycloserine

NRX-101

PTSD Preclinical oral Zeta Surgical, Inc.

D-cycloserine/lurasidone fixed dose combination

NRX-101

Treatment-Resistant Major Depressive Disorder Phase 2 oral

Technology platforms

NMDA platform

NMDA receptor-targeting platform for central nervous system disorders including suicidal depression, chronic pain, and PTSD

Targets: NMDA

Biotech Distilled coverage (9)

2026-06-24 UPDATE: NRx Pharmaceuticals (NRXP) - Kadima Sues, Zeta Goes Live
2026-06-03 UPDATE: NRx Pharmaceuticals (NRXP) - The Print Lands at $3.50
2026-06-02 UPDATE: NRx Pharmaceuticals (NRXP) - The Underwritten Raise Finally Prints
2026-05-16 UPDATE: NRx Pharmaceuticals (NRXP) - The ATM Receipts Arrive (And a Swiss Surprise) 🔒 Paid
2026-05-08 UPDATE: NRx Pharmaceuticals (NRXP) - The Fertilizer Trial Gets a Green Light 🔒 Paid
2026-04-27 UPDATE: NRx Pharmaceuticals (NRXP) - The Hail Mary Becomes a Layup 🔒 Paid
2026-03-21 UPDATE: NRX Pharmaceuticals (NRXP) - The FDA Blinks... 🔒 Paid
2026-02-14 UPDATE: NRx Pharmaceuticals (NRXP) — The Proxy Drops (And the Math is Ugly) 🔒 Paid
2026-01-13 NRx Pharmaceuticals (NRXP): Scientific Deep Dive for KETAFREE™ 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.